Safety and interactions of new antifungals in stem cell transplant recipients

Expert Opinion on Drug Safety

Volumn 11, Issue 5, 2012, Pages 803-818

  Girmenia, Corrado ^a   Iori, Anna Paola ^a  

^a POLICLINICO UMBERTO I   (Italy)

Author keywords

allogeneic HSCT; antifungals; interactions; toxicity

Indexed keywords

ALPRAZOLAM; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CARBAMAZEPINE; CASPOFUNGIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DIAZEPAM; DIGOXIN; FLUCONAZOLE; IMATINIB; ITRACONAZOLE; LOPERAMIDE; METHYLPREDNISOLONE; MICAFUNGIN; MIDAZOLAM; OMEPRAZOLE; PHENYTOIN; POLYENE; POSACONAZOLE; RAPAMYCIN; TACROLIMUS; TEMAZEPAM; TRIAZOLAM; UNINDEXED DRUG; VINCA ALKALOID; VORICONAZOLE; WARFARIN;

ABDOMINAL PAIN; ABNORMAL VISION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC PROPHYLAXIS; ARTHRALGIA; ASPERGILLOSIS; BIOTRANSFORMATION; CANDIDIASIS; CELL DEATH; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEVER; FLUSHING; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION; GRAFT VERSUS HOST REACTION; HALLUCINATION; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INSOMNIA; LIVER CELL DAMAGE; LIVER FUNCTION TEST; LIVER TOXICITY; LOADING DRUG DOSE; LONG TERM CARE; MULTICENTER STUDY (TOPIC); NAUSEA; NEPHROTOXICITY; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; POTASSIUM BLOOD LEVEL; PREGNANCY; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SWELLING; TACHYCARDIA; THROMBOCYTOPENIA; VISUAL DISORDER; VOMITING;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; DRUG INTERACTIONS; ECHINOCANDINS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOSES; OPPORTUNISTIC INFECTIONS; PHARMACOVIGILANCE; RENAL INSUFFICIENCY; STEM CELL TRANSPLANTATION; TRIAZOLES;

EID: 84865516587     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.712111     Document Type: Review

References (76)

1. Marr KA. Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Curr Opin Oncol 2010;22(2):138-42
2. Asano-Mori Y. Fungal infections after hematopoietic stem cell transplantation. Int J Hematol 2010;91(4):576-87
3. Wilson DT, Drew RH, Perfect JR. Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. Mycopathologia 2009;168(6):313-27
4. Girmenia C, Barosi G, Aversa F, et al. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clin Infect Dis 2009;49(8):1226-36
5. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011;46(5):709-18
6. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis (2011):52(4):e56-93
7. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious diseases Society of America. Clin Infect Dis 2008;46(3):327-60 (Pubitemid 351265310)
8. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious diseases Society of America. Clin Infect Dis(2009):48 (5):503-35
9. Leather HL. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplant 2004;33(2):137-52 (Pubitemid 38180925)
10. Gubbins PO, Heldenbrand S. Clinically relevant drug interactions of current antifungal agents. Mycoses 2010; 53(2):95-113
11. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103(4):1557-9 (Pubitemid 38168678)
12. Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents 2006;27(Suppl 1):12-16 (Pubitemid 43775910)
13. Jansen J, Akard LP, Wack MF, et al. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation. Mycoses 2006;49(5):397-404 (Pubitemid 44213882)
14. Ito JI, Chandrasekar PH, Hooshmand-Rad R. Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA). Bone Marrow Transplant 2005;36(10):873-7 (Pubitemid 41655613)
15. Wingard JR. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 1997;19(4):343-7 (Pubitemid 27096066)
16. Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005;40(Suppl 6):S414-21 (Pubitemid 40563299)
17. El-Cheikh J, Faucher C, Fürst S, et al. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2007;39(5):301-6 (Pubitemid 46322637)
18. Roman E, Osunkwo I, Militano O, et al. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr Blood Cancer 2008;50(2):325-30
19. Krüger WH, Rüssmann B, de Wit M, et al. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematol 2005;113(2):104-8 (Pubitemid 40522813)
20. Groll AH, Silling G, Young C, et al. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother 2010;54(10):4143-9
21. Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 2009;18(9):1279-95;
22. Erratum in: Expert Opin Investig Drugs. 2009 Dec;18 (12):1967
23. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010;116(24):5111-18
24. Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011;155(3):318-27
25. Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants (VOSIFI) study group and the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients. Haematologica 2011; 96(2):e9-10; author reply e11
26. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356(4):335-47; (Pubitemid 46148776)
27. Erratum in: N Engl J Med. 2007 Jul 26;357(4):428
28. Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007;67(2):269-98
29. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45(7):649-63 (Pubitemid 43990568)
30. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis 2002;35(10):1273-5
31. Moudgal VV, Sobel JD. Antifungal drugs in pregnancy: a review. Expert Opin Drug Saf 2003;2(5):475-83
32. Clancy CJ, Nguyen MH. Long-term voriconazole and skin cancer: is there cause for concern? Curr Infect Dis Rep 2011;13(6):536-43
33. Cowen EW, Nguyen JC, Miller DD, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010;62(1):31-7
34. Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45:1610-17 (Pubitemid 351411847)
35. Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5:775-85 (Pubitemid 41688982)
36. Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc 2011; 86(8):805-17
37. Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm 2006;63(18):1693-703 (Pubitemid 44413505)
38. Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections, part 2. Am J Health Syst Pharm 2006;63(19):1813-20 (Pubitemid 44477452)
39. Wiederhold NP, Lewis JS II. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother 2007;8(8):1155-66 (Pubitemid 46929308)
40. Hiemenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005;49(4):1331-6 (Pubitemid 40463357)
41. Ascher S, Smith PB, Benjamin DK Jr. Safety of micafungin in infants: insights into optimal dosing. Expert Opin Drug Saf 2011;10(2):281-6
42. George J, Reboli AC. Anidulafungin: when and how? The clinician's view. Mycoses 2012;55(1):36-44
43. Trenschel R, Ditschkowski M, Elmaagacli AH, et al. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant 2005;35(6):583-6 (Pubitemid 40450456)
44. de Fabritiis P, Spagnoli A, Di Bartolomeo P, et al. Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant 2007;40(3):245-9 (Pubitemid 47108468)
45. Herbrecht R, Maertens J, Baila L, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010;45(7):1227-33
46. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39(10):1407-16 (Pubitemid 39518200)
47. Sirohi B, Powles RL, Chopra R, et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006;38(1):47-51 (Pubitemid 43923089)
48. Hashino S, Morita L, Takahata M, et al. Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol 2008;87(1):91-7
49. Furrer K, Schaffner A, Vavricka SR, et al. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation. Swiss Med Wkly 2002;132(23-24):316-20 (Pubitemid 35033787)
50. Gubbins PO, Penzak SR, Polston S, et al. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 2002;22(8):961-71 (Pubitemid 34831291)
51. Ringdén O, Andström E, Remberger M, et al. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant 1994; 14(Suppl 5):S10-14
52. Nivoix Y, Levêque D, Herbrecht R, et al. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008;47:779-92
53. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009;53:24-34
54. Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012;56(6):2806-13
55. Hussaini T, Rüping MJ, Farowski F, et al. Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy 2011;31(2):214-25
56. Howard SJ, Felton TW, Gomez-Lopez A, Hope WW. Posaconazole: the case for therapeutic drug monitoring. Ther Drug Monit 2012;34(1):72-6
57. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006;26(12):1730-44 (Pubitemid 44885328)
58. Pfizer, Inc. Vfend (voriconazole) package insert. New York, NY: 2008
59. Romero AJ, Le Pogamp P, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant recipients. Clin Pharmacol Ther 2002;71:226-34 (Pubitemid 34311451)
60. Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002;46:3091-3
61. Tintillier M, Kirch L, Goffin E, et al. Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol Dial Transplant 2005;20:664-5 (Pubitemid 40378452)
62. Mori T, Aisa Y, Kato J, et al. Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of oral solution itraconazole. Int J Hematol 2009;90(1):103-7
63. Trifilio SM, Scheetz MH, Pi J, Mehta J. Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring. Bone Marrow Transplant 2010;45(8):1352-6
64. Busca A. The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation. Expert Opin Biol Ther 2011;11(6):687-97
65. Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45:1610-17 (Pubitemid 351411847)
66. Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5:775-85 (Pubitemid 41688982)
67. Cornely OA, Helfgott D, Langston A, et al. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob Agents Chemother 2012; Epub ahead of print
68. Krishna G, Ma L, Vickery D, et al. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2009;53(11):4749-52
69. Berge M, Chevalier P, Benammar M, et al. Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis. Ther Drug Monit 2009;31(3):396-9
70. Sansone-Parsons A, Krishna G, Martinho M, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007;27(6):825-34 (Pubitemid 46849426)
71. Kohl V, Müller C, Cornely OA, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother 2010;54(1):207-12
72. Swiss Compendium of Drugs. Product information caspofungin. Documed AG; Basel, Switzerland: 2009
73. Christopeit M, Eikam M, Behre G. Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity. Mycoses 2008;51(Suppl 1):19-24 (Pubitemid 351678032)
74. Saner F, Gensicke J, Rath P, et al. Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection 2006;34(6):328-32 (Pubitemid 44968925)
75. Fukuoka N, Imataki O, Ohnishi H, et al. Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. Transplant Proc 2010;42(7):2725-30
76. Dowell JA, Stogniew M, Krause D, et al. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol 2007;47(3):305-14 (Pubitemid 46294710)